Evidence map›Paper›PMID 42185515›Full record

ArticleCommunications biology2026

Scaling antibody language models improves structure aware representation for antibody engineering.

Shengyuan Bai, Zijing Liu, Bin Feng, Jiying Zhang, Yu Li

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shengyuan Bai *International Digital Economy Academy, Shenzhen, China.
Zijing Liu *International Digital Economy Academy, Shenzhen, China.ORCID 0000-0002-0189-7409
Bin FengInternational Digital Economy Academy, Shenzhen, China.
Jiying ZhangInternational Digital Economy Academy, Shenzhen, China.
Yu LiInternational Digital Economy Academy, Shenzhen, China. liyu@idea.edu.cn.ORCID 0000-0003-1865-8276

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody language models have emerged as powerful tools in antibody engineering by capturing patterns in sequences to innovate discovery and optimization. While recent advances in machine learning have significantly enhanced this field, current approaches often struggle to capture the full structural complexity inherent in antibody sequences. To address this, we present AbLingua, a family of language models pre-trained on antibody sequences. The largest model in this family contains 1.7 billion parameters and is trained on 1.4 billion sequences, making it the largest encoder-based language model specific to antibodies. AbLingua employs an advanced tokenization method that expands the vocabulary to a level comparable with human language, which enables the model to capture complex structural motifs influencing antibody behavior. Building upon this method, AbLingua introduces an improved pre-training approach that processes amino acid units to better represent structural interdependencies. We demonstrate that AbLingua achieves superior performance across multiple applications, including paratope prediction, neutralizing capacity assessment, and therapeutic antibody design. Furthermore, it excels in the unsupervised classification of B-cell developmental stages and virus-specific antibodies. Our findings demonstrate that the synergy of advanced tokenization, robust scaling laws, and curated datasets constitutes a superior foundation for antibody engineering, significantly driving development efficiency.

Indexed as

AntibodiesProtein EngineeringHumansLarge Language ModelsMachine LearningRepresentation Machine LearningAntibodies

Identifiers

PMID42185515
PMCPMC13484476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.